Scientists discover a new method for the early detection of subclinical atherosclerosis in plasma samples- study review by BIOMEDICA CRO
A study published in the journal eBiomedicine identifies new biomarkers that predict the presence of subclinical atherosclerosis.
In the new investigation, the research team analyzed a collection of 880 blood plasma samples obtained from PESA (Progression and Early detection of Subclinical Atherosclerosis) study participants. It was identified that PIGR, IGHA2, APOA, HPT and HEP2 were associated with subclinical atherosclerosis independently from traditional risk factors at both time points in the discovery and validation cohorts.
Summarizing the findings, José Luis Martín Ventura, a CIBERCV scientist at the IIS-FJD-UAM and one of the study coordinators, said “the main contribution of this study is the development of a biomarker panel that can identify the presence of atherosclerosis in healthy, asymptomatic people, including individuals with none of the classical cardiovascular risk factors.”
Measuring plasma levels of IGHA2, APOA and HPT by immunoturbidimetry provides valuable information on the presence of subclinical atherosclerosis. This approach may thus provide an affordable alternative to cardiovascular imaging for the identification of subclinical atherosclerosis.
To find more information kindly visit eBiomedicine journal, articles, “Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis”.
Early prevention is the best approach to combatting any disease pandemic.
BIOMEDICA CRO is proud to participate in research on new biomarkers, preclinical trials, drugs and vaccines development. Our team is ready to collect various high-quality human biospecimens (whole blood, serum, PBMCs, plasma samples, tissue samples, other biofluids, etc.) and associated data from donors with different diseases, including atherosclerosis and matched healthy controls.
Because of the war in Ukraine, we had to pause our operations, but we redirect all your requests to our trusted international partner. From every completed project order by them, we will receive a commission which will be spent for the defense of Ukraine (not less than 50%) and support of the Ukrainian operation team. Once the Ukrainian sky is clear and safe, we will continue to provide you with high-quality service in the field of biospecimen collection.
Please email us to start our collaboration: office@biomedica-cro.com / LinkedIn.
